STMN1 and glioma: Our study showed that immune checkpoints currently targeted in ongoing clinical trials in patients with glioma, such as TIM-3 and LAG-3 (NCT03058290, NCT02658981), were low and infrequently expressed in the freshly isolated patient immune cells and therefore not expected to be therapeutically beneficial for the majority of patients.